Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06419582 · ClinicalTrials.gov registry record · Phase 2
BHV-7000 Acute Treatment of Bipolar Mania
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT06419582 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 274 participants.
The verdict
NCT06419582, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Interventions
- DRUG Placebo
- DRUG BHV-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06419582
The ClinicalTrials.gov registry entry for NCT06419582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06419582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06419582 about?
NCT06419582 is a clinical study titled "BHV-7000 Acute Treatment of Bipolar Mania". The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
What is the current status of trial NCT06419582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2024-05-28. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT06419582?
The interventions under investigation include: Placebo (DRUG), BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06419582?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.